The Journal of Urology
Volume 181, Issue 3 , Pages 963-971, March 2009

A New Vision for the Study of Benign Prostate Disease: The NIDDK Prostate Research Strategic Plan

  • Chris Mullins

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland
    • Financial interest and/or other relationship with AUA Research Council.
  • ,
  • Steven A. Kaplan

      Affiliations

    • Weill Cornell Medical College, New York, New York
    • Corresponding Author InformationCorrespondence: Department of Urology, Weill Cornell Medical College, F9-West, Box 261, 525 East 68th St., New York, New York 10065 (telephone: 212-746-4811; FAX: 212-746-5329)

Received 12 October 2008 published online 16 January 2009.

Purpose

The American population continues to enjoy a steady increase in life expectancy. A major goal for this population is to maintain and improve quality of life as it ages. For men a major source of age related health burden is benign disorders of the prostate which, despite much research, remain poorly defined and require greater advancement in prevention and treatment. Thus, there is a substantial need to develop a long-range vision to focus and promote efforts to better understand and manage benign prostate disease. In response the National Institute of Diabetes and Digestive and Kidney Diseases convened a panel of key opinion leaders including basic researchers, translational scientists, epidemiologists, and clinicians and clinical researchers to develop a comprehensive strategic plan to advance research in benign prostate disease.

Materials and Methods

The overall mission statement of this effort is “To discuss, evaluate, and propose research needs and a long-range research agenda (ie a strategic plan) for NIDDK grant portfolios related to research into benign prostate disease.” Implementation and practical application of this strategic plan will require a partnership of the scientific community, the Federal Government, and other public and private organizations and institutions.

Results

This focused group of research and thought leaders identified 4 major areas of key significance for future investigation: basic science, epidemiology/population based studies, translational opportunities and clinical sciences. Great opportunities are identified within these 4 areas to develop new insights, and translate findings for benign prostate diseases and related syndromes between the research laboratory and the clinical setting.

Conclusions

The product of these efforts, the National Institute of Diabetes and Digestive and Kidney Diseases Prostate Research Strategic Plan, represents a blueprint that researchers and Federal Government can use to review where the field has been, define where the field is and, most importantly, identify where and how future research efforts should be directed. To accomplish this goal many priorities must be addressed, including the need to create more effective lines of communication among scientific disciplines to improve translation of research findings and ultimately advance patient treatment. The overall goals and missions of the National Institute of Diabetes and Digestive and Kidney Diseases Prostate Research Strategic Plan, along with key scientific recommendations and priorities for the major areas of focus, are summarized.

Key Words: National Institutes of Health (U.S.), prostate, epidemiology, research

Abbreviations and Acronyms: BPH, benign prostatic hyperplasia, CP/CPPS, chronic prostatitis/chronic pelvic pain syndrome, LUTS, lower urinary tract symptoms, NIDDK, the National Institute of Diabetes and Digestive and Kidney Diseases, NIH, National Institutes of Health, QOL, quality of life

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-5347(08)03060-7

doi:10.1016/j.juro.2008.11.033

The Journal of Urology
Volume 181, Issue 3 , Pages 963-971, March 2009